NCT06598306Recruiting
Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Summary
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Inclusion criteria
• Participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent. • Participants with histologically or cytologically confirmed ES-SCLC that progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC. Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease. • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. • Participants must have adequate organ function (cardiac, pulmonary, kidney, and liver). • Participants must be able to have SC injections administered in the abdomen. • Participants without measurable disease or tumor tissue (fresh biopsy or archival) available may be permitted after discussion with and approval by Amgen Medical Monitor.
Exclusion criteria
• Participants that have received prior DLL3 targeted therapy. • Participants with untreated or symptomatic brain metastases or those requiring therapy with steroids. • Note: Participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (Amgen Medical Monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment). • Participants with leptomeningeal disease. • Participants with baseline oxygen requirement.
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Countries
- Switzerland, Germany, United States, Australia, Belgium, China, Japan, Poland, Spain, Turkey (Türkiye)
- Sponsor
- Amgen(Industry)
- Protocol no.
- 20230298
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Drug
Treatments studied
- Tarlatamab
Collaborators
BeOne Medicines
Locations · 31
- Chur, SwitzerlandKantonsspital GraubuendenRecruiting at this site
- Fribourg, SwitzerlandFreiburg SpitalRecruiting at this site
- Winterthur, SwitzerlandKantonsspital WinterthurRecruiting at this site
- Regensburg, GermanyUniversitaetsklinikum RegensburgRecruiting at this site
- Würzburg, GermanyUniversitaetsklinikum WuerzburgRecruiting at this site
- Los Angeles, United StatesUniversity of Southern California, Norris Comprehensive Cancer CenterRecruiting at this site
- Chicago, United StatesUniversity of Illinois ChicagoRecruiting at this site
- Ann Arbor, United StatesTrinity Health Saint Joseph Mercy Ann ArborRecruiting at this site
- Sioux Falls, United StatesAvera Cancer InstituteRecruiting at this site
- Houston, United StatesUniversity of Texas MD Anderson Cancer CenterRecruiting at this site
- Seattle, United StatesSwedish Cancer InstituteRecruiting at this site
- Camperdown, AustraliaChris OBrien LifehouseRecruiting at this site
- Waratah, AustraliaCalvary Mater Newcastle HospitalRecruiting at this site
- Melbourne, AustraliaThe Alfred HospitalRecruiting at this site
- Ghent, BelgiumUniversitair Ziekenhuis GentRecruiting at this site
- Leuven, BelgiumUniversitair Ziekenhuis Leuven - Campus GasthuisbergRecruiting at this site
- Liège, BelgiumCentre Hospitalier Universitaire de Liege - Sart TilmanRecruiting at this site
- Changchun, ChinaJilin Cancer HospitalRecruiting at this site
- Shanghai, ChinaShanghai Pulmonary HospitalRecruiting at this site
- Okayama, JapanOkayama University HospitalRecruiting at this site
- Wakayama, JapanWakayama Medical University HospitalRecruiting at this site
- Gdansk, PolandUniwersyteckie Centrum KliniczneRecruiting at this site
- Lodz, PolandInstytut Centrum Zdrowia Matki PolkiRecruiting at this site
- Przemyśl, PolandWojewodzki Szpital im Sw Ojca Pio w PrzemysluRecruiting at this site
- Málaga, SpainHospital Regional Universitario de MalagaRecruiting at this site
- Barcelona, SpainHospital Universitari Vall d HebronRecruiting at this site
- Valencia, SpainHospital Universitari i Politecnic La FeRecruiting at this site
- Madrid, SpainHospital Universitario 12 de OctubreRecruiting at this site
- Adana, Turkey (Türkiye)Adana Sehir Egitim ve Arastirma HastanesiRecruiting at this site
- Ankara, Turkey (Türkiye)Ankara Bilkent Sehir HastanesiRecruiting at this site
In total, worldwide, all 31 sites listed in the registry are recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: June 26, 2026).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
+ 1 more location
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.